Halozyme Therapeutics (HALO) shares outstanding

Shares outstanding · fiscal 2025
123.90M

Halozyme Therapeutics (HALO) had 123.90M diluted shares on average in fiscal 2025 (the year ended December 31, 2025). That is 4.3% lower than the 129.42M of fiscal 2024. Figures as of 18 Nov 2026, 12:33 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Shares outstanding, fiscal 2025
123.90M
Change on fiscal 2024
−4.3%
Growth, 5 years
−2.6% a year
Growth, 10 years
−0.2% a year
Highest on record
146.80Mfiscal 2021
Lowest on record
123.90Mfiscal 2025
Fiscal years on record
112015–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Halozyme Therapeutics shares outstanding, in more detail

The market data feed counts 114.01M shares outstanding today.

Over the five fiscal years to 2025 the diluted share count shrank at a compound 2.6% a year; over ten years the rate was −0.2% a year. Across the 11 fiscal years on record (2015–2025), the highest was 146.80M in fiscal 2021 and the lowest 123.90M in fiscal 2025.

History · 11 fiscal years

Shares outstanding by fiscal year

Halozyme Therapeutics shares outstanding, year by year

Halozyme Therapeutics (HALO) shares outstanding by fiscal year
Fiscal yearShares outstandingChangeYear ended
2025123.90M 4.3% down
2024129.42M 3.6% down
2023134.20M 4.6% down
2022140.61M 4.2% down
2021146.80M 3.8% up
2020141.46M 2.0% down
2019144.33M 0.5% up
2018143.60M 3.3% up
2017139.07M 8.7% up
2016127.96M 1.0% up
2015126.70M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The share count for each fiscal year is the diluted weighted average the company reports with its earnings per share, re-based for later stock splits; the number outstanding today comes from the market data feed.

How to read it

A falling count means buybacks are giving each remaining share a larger slice of the company; a rising one means owners are being diluted.

Shares outstanding at health care companies of similar size

Shares outstanding of Halozyme Therapeutics and comparable companies
CompanyShares outstandingFiscal year
Fresenius Medical Care FMS582.38M2025
Kymera Therapeutics KYMR84.49M2025
DaVita DVA75.89M2025
Halozyme Therapeutics HALO123.90M2025
Universal Health Services UHS64.46M2025
Repligen RGEN56.56M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on HALO

Halozyme Therapeutics, figure by figure

Halozyme Therapeutics (HALO) overview: price, valuation and scorecardAll health care companies by market value

Halozyme Therapeutics shares outstanding: questions and answers

How many shares does Halozyme Therapeutics have?

Halozyme Therapeutics (HALO) had 123.90M diluted shares on average in fiscal 2025 (the year ended December 31, 2025). That is 4.3% lower than the 129.42M of fiscal 2024. The market data feed counts 114.01M shares outstanding today.

What is the growth rate of Halozyme Therapeutics's diluted share count?

Over the five fiscal years to 2025 the diluted share count shrank at a compound 2.6% a year; over ten years the rate was −0.2% a year.

What are the highest and lowest diluted share count figures on record for Halozyme Therapeutics?

Across the 11 fiscal years on record (2015–2025), the highest was 146.80M in fiscal 2021 and the lowest 123.90M in fiscal 2025.

How is Halozyme Therapeutics's diluted share count calculated?

The share count for each fiscal year is the diluted weighted average the company reports with its earnings per share, re-based for later stock splits; the number outstanding today comes from the market data feed. For Halozyme Therapeutics it is on record here for 11 fiscal years, 2015 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Halozyme Therapeutics (HALO) shares outstanding”, data as of 18 November 2026. https://funkfolio.com/stock/HALO/shares-outstanding

Underlying data: the company's filings with the SEC and Yahoo Finance.